Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Stryker Corporation — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.33 (market cap $41.13B), while Stryker Corporation trades at $279.24 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 2.6× iShares 7-10 Year Treasury Bond ETF's market cap, and Stryker Corporation pays a 1.27% dividend while iShares 7-10 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Stryker Corporation for 20 Days on average.
| IEF | SYK | |
|---|---|---|
Market Cap | $41.13B | $106.24B |
Volume | 10,340,382 | 2,982,001 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $388.35 |
52-Week Low | $88.92 | $269.75 |
Typical Hold Time | 108 Days | 20 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.295 with a modest 0.21% daily gain amid a challenging bond market environment. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent Treasury yield volatility and bond market selloffs have created headwinds for fixed income ETFs, while dividend distributions continue with recent payouts around $0.31-0.33 per share.
The outlook remains cautious as rising Treasury yields and inflation concerns pressure bond ETFs. While current yields provide income appeal, further rate increases could depress prices. Investors face the trade-off between defensive positioning and potential capital depreciation if the bond rout continues.
Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.
Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
